Clinical Trial Update: An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating PF-02341066 (crizotinib) in patients with advanced non-small cell lung cancer with ALK gene alterations has completed, and i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• PF-02341066 (crizotinib) (crizotinib)

Snippet

Sponsor: Pfizer | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: COMPLETED | Results posted: 2016-06-09